(IN BRIEF) Novartis has announced plans to establish a 46,000-square-foot radioligand therapy manufacturing facility in Denton, Texas, with operations expected to begin in 2028. The new site will expand the company’s U.S. manufacturing network and support growing demand for targeted … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Switzerland
Tagged advanced manufacturing, bioengineering jobs, cancer treatment manufacturing, Dallas Fort Worth biotech, Denton Texas, Greg Abbott, Novartis, Novartis Expands Radioligand Therapy Network with New Manufacturing Site in Denton Texas, Novartis Strengthens US Radioligand Therapy Production with Planned Texas Manufacturing Investment, nuclear medicine, oncology pipeline, pharmaceutical manufacturing, radioligand therapy RLT, radiopharmaceuticals, targeted radiation therapy, US investment program, Vas Narasimhan
(IN BRIEF) Novartis announced a definitive agreement to acquire Avidity Biosciences for USD 12 billion in cash, in a move that strengthens its neuroscience franchise and accelerates its xRNA therapeutic strategy. The acquisition brings Avidity’s late-stage programs in myotonic dystrophy … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged acquisition, Antibody Oligonucleotide Conjugates, AOCs, Avidity Biosciences, Basel, biopharma, biopharmaceutical innovation, biotechnology, clinical research, DM1, DMD, drug development, Duchenne muscular dystrophy, EXPLORE44 trial, facioscapulohumeral muscular dystrophy, FORTITUDE trial, FSHD, genetic medicine, HARBOR trial, muscle-directed therapy, myotonic dystrophy type 1, neuromuscular diseases, Novartis, Novartis Strengthens Neuroscience Franchise with Acquisition of Avidity Biosciences and Its Muscle-Directed RNA Platform, RNA delivery, RNA therapeutics, San Diego, SpinCo, Vas Narasimhan, xRNA strategy
(IN BRIEF) Novartis has appointed Mukul Mehta as CFO and Executive Committee member effective March 16, 2026. He will replace long‑time CFO Harry Kirsch, who retires on March 15, 2026, after 22 years at the company. Kirsch oversaw major strategic … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged 22-year career, Alcon spinoff, appointment, business planning and analysis, CFO appointment, digital finance, ECN, Executive Committee, focused medicines strategy, global finance leadership, GSK divestiture, Harry Kirsch, INSEAD, Jamnalal Bajaj Institute of Management Studies, leadership, March 16 2026, Mukul Mehta, Novartis, retirement, Roche divestiture, Sandoz spinoff, TAX, Vas Narasimhan
(IN BRIEF) Novartis, a leading pharmaceutical company, presented its ‘pure play’ innovative medicines strategy and focused Research and Development (R&D) pipeline at an event in London. The company’s CEO, Vas Narasimhan, emphasized Novartis’ transformation into an innovative medicines-focused firm, highlighting … Read the full press release
Posted in Business, Industrial, Management, Media, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged 'Pure Play' Innovative Medicines Strategy, London Event, Novartis, R&D Pipeline, Vas Narasimhan
Topline results from the randomized EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days The secondary … Read the full press release
(PRESS RELEASE) BASEL, 22-Mar-2021 — /EuropaWire/ — Swiss multinational pharmaceutical Novartis appoints Karen L. Hale as Chief Legal Officer. She succeeds Shannon Klinger. Karen will be based in Basel, Switzerland and will join the Executive Committee of Novartis (ECN) and … Read the full press release
Posted in Law, News, Pharma & Biotech, Switzerland
Tagged Abbott, AbbVie, appointment, CEO, Chief Legal Officer, College of William and Mary, compliance, Duke University, healthcare legal, Karen L. Hale, legal, M.D., Novartis, Pharmaceutical, racial justice, Shannon Klinger, Sidley & Austin, Tom Kendris, Vas Narasimhan
(PRESS RELEASE) BASEL, 15-Mar-2019 — /EuropaWire/ — Sandoz’s current Region Head Europe Francesco Balestrieri has just been appointed ad-interim CEO of Sandoz reporting directly to Vas Narasimhan, CEO, Novartis. The change is made as the current CEO of Sandoz, a … Read the full press release
Posted in Healthcare, Management, News, Pharma & Biotech, Switzerland
Tagged ad-interim CEO, appointment, biosimilar products, CEO, Francesco Balestrieri, generics, leadership, medicine, Novartis, Richard Francis, Sandoz, Sandoz transformation, transformation, transformative treatments, Vas Narasimhan
Munich, Germany, 28-3-2014 — /EuropaWire/ — Sandoz announced today that Vasant (Vas) Narasimhan, MD, MPP, has been appointed Head of Sandoz Biopharmaceuticals & Oncology Injectables effective April 1, 2014. Vas, currently Global Head of Development at Novartis Vaccines, succeeds Ameet Mallik who will … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?